Abstract
Aim: Bromodomain and extraterminal (BET) proteins are important mediators of inflammation through epigenetic remodelling. Diabetic patients have an increased risk of developing atherosclerosis and present basal inflammation in monocytes. The RVX-208 compound is an epigenetic BET inhibitor with anti-inflammatory properties, shown with in vivo and in vitro studies. We aimed to determine whether using RVX-208 can have ex vivo anti-inflammatory properties on monocytes from diabetic patients, challenged with lipopolysaccharide (LPS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
